Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights

Rhea-AI Summary

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) will host a conference call on August 5, 2022, at 8:00 a.m. ET to discuss its financial results for Q2 2022, which ended June 30, 2022, along with recent corporate highlights. Domestic callers can dial (844) 200-6205 or (929) 526-1599 for international calls, using access code 908644. A live audio webcast will also be available on Aldeyra's website and will remain archived for 90 days. Aldeyra focuses on innovative therapies for immune-mediated diseases, with key products in development addressing various conditions.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Friday, August 5, 2022 to report financial results for the quarter ended June 30, 2022 and discuss recent corporate highlights.

The dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 for international callers. The access code is 908644. A live audio webcast of the conference call also will be accessible from the “Investors & Media” section of Aldeyra’s website at https://ir.aldeyra.com/.

After the live webcast, the event will remain archived on Aldeyra’s website for 90 days.

About Aldeyra

Aldeyra is a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases. Our approach is to discover pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in late-stage clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 clinical testing for the treatment of systemic immune-mediated diseases. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220728005954/en/

Investor & Media:

Scott Solomon

Sharon Merrill Associates, Inc.

Tel: (857) 383-2409

ALDX@investorrelations.com

Source: Aldeyra Therapeutics, Inc.

FAQ

When will Aldeyra Therapeutics report its Q2 2022 financial results?

Aldeyra Therapeutics will report its Q2 2022 financial results on August 5, 2022, at 8:00 a.m. ET.

How can I access the Aldeyra conference call?

You can access the Aldeyra conference call by dialing (844) 200-6205 for domestic calls or (929) 526-1599 for international calls, using access code 908644.

What is the focus of Aldeyra Therapeutics?

Aldeyra Therapeutics specializes in developing therapies for immune-mediated diseases, targeting multiple pathways to minimize toxicity.

Where can I find the archived conference call?

The archived conference call will be available on Aldeyra's website for 90 days following the live event.